A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2019
At a glance
- Drugs Enadenotucirev (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Proof of concept
- Acronyms OCTAVE
- Sponsors PsiOxus Therapeutics
- 22 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Nov 2019.
- 22 Feb 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2019.
- 20 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.